Description

Lurbinectedin is a synthetically produced marine-derived antineoplastic agent belonging to the tetrahydroisoquinoline class. Its primary value lies in its potent and selective mechanism of action, which inhibits active transcription and induces DNA double-strand breaks, leading to apoptosis in cancer cells. This product is essential for pharmaceutical research and development, specifically targeting the formulation of therapies for small cell lung cancer (SCLC) and other solid tumors. We supply high-purity Lurbinectedin CAS NO 497871-47-3 to support critical work in oncology drug discovery and clinical manufacturing.

Application

• Oncology Pharmaceutical R&D: Primary active pharmaceutical ingredient (API) for the development of novel cancer therapeutics.
• Clinical Trial Material: Sourcing of GMP-grade material for Phase I-III clinical studies in various cancers.
• Small Cell Lung Cancer (SCLC) Treatment: Key component in the formulation of approved and investigational drugs for relapsed SCLC.
• Mechanistic Studies: Used in biochemical and cellular assays to study transcription inhibition and DNA damage response pathways.
• Preclinical Research: Evaluation of efficacy and safety in in vitro and in vivo cancer models.
• Drug Combination Studies: Research into synergistic effects with other chemotherapeutic agents or immunotherapies.
• Reference Standard: Serves as a high-purity analytical standard for quality control and pharmacokinetic studies.
• Generic Drug Development: Supporting the development of biosimilar or generic versions upon patent expiry.

Basic Information

Product Name	Lurbinectedin
CAS No.	497871-47-3
Molecular Formula	C41H44N4O10S
Molecular Weight	784.88 g/mol
Synonyms	PM01183; Zepsyre; Lurbinectedina; (1'R,2R,2'S,3'R,4'S,5'R,6'S)-6-[(2S)-2-Hydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)ethyl]-2-methoxy-2',3',4',5',5',6'-hexahydro-6'H-spiro[1,3-dioxolane-2,11'-[2]benzoxacyclotetradecin]-4'-carboxamide; 7,11-Methano-7H-cycloocta[1,2-b:5,6-b']diquinolin-7-one, 1,2,3,10,11,11a-hexah-12-(hydroxymethyl)-4-(trifluoromethyl)-, (7S,11aS)-
EINECS	Contact for details

Quality Control

Our Lurbinectedin is manufactured under strict quality systems to ensure it meets the exacting standards required for pharmaceutical applications. Each batch undergoes comprehensive analytical testing, including identity confirmation, purity assay, and detailed impurity profiling via advanced techniques like HPLC and LC-MS. Certificates of Analysis (COA) are provided, detailing compliance with in-house specifications aligned with ICH guidelines. We support development from non-GMP research to cGMP-grade material for clinical use.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature, typically between 15-25°C, in a dry environment. This compound is hygroscopic (moisture-sensitive); therefore, the container must be kept tightly sealed to prevent degradation from atmospheric moisture. For long-term storage, consider desiccants or an inert atmosphere.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single unknown impurity ≤ 0.5%
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.